USA • New York Stock Exchange • NYSE:CRL • US1598641074
The current stock price of CRL is 189.21 USD. In the past month the price decreased by -12.2%. In the past year, price increased by 15.52%.
ChartMill assigns a technical rating of 5 / 10 to CRL. When comparing the yearly performance of all stocks, CRL is one of the better performing stocks in the market, outperforming 71.92% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to CRL. CRL has only an average score on both its financial health and profitability.
Over the last trailing twelve months CRL reported a non-GAAP Earnings per Share(EPS) of 10.55. The EPS increased by 4.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.11% | ||
| ROE | -2.45% | ||
| Debt/Equity | 0.64 |
22 analysts have analysed CRL and the average price target is 208.66 USD. This implies a price increase of 10.28% is expected in the next year compared to the current price of 189.21.
For the next year, analysts expect an EPS growth of 0.17% and a revenue growth -0.59% for CRL
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 21.87 | 203.77B | ||
| DHR | DANAHER CORP | 25.5 | 152.395B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 151.95 | 49.166B | ||
| A | AGILENT TECHNOLOGIES INC | 21.41 | 36.753B | ||
| IQV | IQVIA HOLDINGS INC | 14.33 | 30.817B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 29.71 | 28.252B | ||
| WAT | WATERS CORP | 26.39 | 22.436B | ||
| ILMN | ILLUMINA INC | 23.12 | 20.416B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.72 | 16.663B | ||
| MEDP | MEDPACE HOLDINGS INC | 32.24 | 15.248B |
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,600 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
CHARLES RIVER LABORATORIES
251 Ballardvale St
Wilmington MASSACHUSETTS 01887 US
CEO: James C. Foster
Employees: 19400
Phone: 17812226000
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. The company is headquartered in Wilmington, Massachusetts and currently employs 18,600 full-time employees. The company went IPO on 2000-06-23. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
The current stock price of CRL is 189.21 USD. The price increased by 3% in the last trading session.
CRL does not pay a dividend.
CRL has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
CRL stock is listed on the New York Stock Exchange exchange.
CHARLES RIVER LABORATORIES (CRL) operates in the Health Care sector and the Life Sciences Tools & Services industry.
The outstanding short interest for CHARLES RIVER LABORATORIES (CRL) is 5.82% of its float.